A Practical Guide to Construction, Commissioning and Qualification Documentation – and Its Critical Role in Achieving Complian

Total Page:16

File Type:pdf, Size:1020Kb

A Practical Guide to Construction, Commissioning and Qualification Documentation – and Its Critical Role in Achieving Complian Commissioning and Qualification This article Reprinted from The Official Journal of ISPE focuses on PHARMACEUTICAL ENGINEERING® July/August 2005, Vol. 25 No. 4 construction contractors who can deliver A Practical Guide to Construction, qualified facilities and Commissioning and Qualification presents the advantages of Documentation – and its Critical Role using a construction in Achieving Compliance contractor who can perform by Wael Allan and Andrew D. Skibo Commissioning and Qualification. ood documentation is essential for Naturally, the initial focus must be on the pharmaceutical and biotech manufac- proper construction and start-up of the facility. turing facilities to achieve regulatory Yet, a well-constructed facility that is on time, compliance. As defined by the Food within budget, and whose every system is per- Gand Drug Administration (FDA), “Validation is forming to specifications is of no value to the a documented program providing a high degree operating company if the associated documen- of assurance that a process/system consistently tation does not effectively support the qualifi- meets pre-determined specifications.” The clear cation process – it is a classic case of failing to presumption is that if the required activities see the forest through trees. In fact, the con- have not been properly documented, then they struction contractor must appreciate the sig- have not been performed. nificance of documentation, and make it an integral part of the con- Figure 1. Validation life cycle. struction planning, im- plementation, and com- missioning process from day one. Note: the term “Con- struction Contractor” is used to indicate a third party company respon- sible for construction, commissioning and qual- ification. This article fo- cuses on construction contractors who can de- liver qualified facilities. It also presents the ad- vantages of using a con- struction contractor who can perform C&Q, as well as construction led rather than design led projects. A “full service provider” could provide all of these activities. These activi- ties could be provided in ©Copyright ISPE 2005 JULY/AUGUST 2005 PHARMACEUTICAL ENGINEERING 1 Commissioning and Qualification part by a Construction Management (CM) contractor, a stages of the project, or the effort required to do it successfully commissioning contractor, a qualification contractor and the is underestimated. For example, on an 18-month project, the operating company. QA/documentation officer should be involved by the first quarter of the project – during the planning phase — to begin Turn Over Package (TOP): to organize the TOP to meet the operating company’s needs Laying the Foundation and expectations. It is well worth the small investment to Good documentation is an essential part of the Quality bring that individual on board early to avoid problems during Assurance (QA) system. For new and renovated facilities, the qualification process, and ultimately, reduce time to Commissioning and Qualification (C&Q) are key aspects of market. This approach eliminates duplication of effort by cost and schedule. Therefore, documentation – in the form of leveraging documentation from commissioning into Installa- the TOP, C&Q protocols, and other required documents – tion Qualification (IQ). IQ is approximately 30% of the quali- plays a pivotal role in ensuring a compliant facility. Every fication effort; by leveraging commissioning documentation, operating company has specific standards and methodologies a savings of approximately 50% of IQ effort could be made, for C&Q. The construction contractor’s job is to make sure resulting in an overall saving of 15% of qualification time. that the TOP enables the operating company to effectively carry out its QA strategy. Therefore, the TOP must be well- The Validation Life Cycle organized, meet the operating company’s expectations, and Just as good documentation is required to achieve regulatory provide the proper level of documentation quality. compliance, clear user specifications that are fully under- To be successful, an integrated documentation process stood by the construction contractor are required to meet the must start very early in the project in conjunction with the operating company’s unique needs and expectations. If the planning of C&Q. It must involve engineering, construction, constructor fails to understand these from the outset, the and qualification/validation. Moreover, project documenta- TOP is likely to be inadequate. Therefore, for every step taken tion requirements, and the roles and responsibilities for the by the operating company, engineers and construction con- operating company, construction contractors, and vendors tractor, a high level of integration is required to ensure that alike, must be clearly defined. the resulting documentation is appropriate, compliant, and Too often, documentation work is delayed until the later structured in a meaningful manner - Figure 1. The diagram Figure 2. Document hierarchy. 2 PHARMACEUTICAL ENGINEERING JULY/AUGUST 2005 ©Copyright ISPE 2005 Commissioning and Qualification illustrates the importance of the “definition” stage for both PHASE DOCUMENT ALL CRITICAL the operating company and the contractor. In all aspects of TYPE SYSTEMS SYSTEMS the life cycle, documentation/data is a very critical element. Good Enhance The operating company’s definitions of specifications and Engineering Documentation process requirements drive the whole project. Specifically, Practice the operating company defines the process, develops proce- Engineering Design Intent B V dures and specifications, and verifies these. In turn, the P&IDs C V construction contractor specifies and installs equipment, and Specifications B B Drawings C* V tests and qualifies making systems ready for validation and operation. This process requires that the construction con- Construction Purchasing B B Vendor B C tractor accurately “translate” the operating company’s defi- Installation C C nitions and expectations into systems, bricks, and mortar. Commissioning Lists B B Otherwise, the succeeding steps – development of the valida- Factory Testing B B tion protocol through change control – will be fraught with Field Testing B V problems, delaying time to market. Start-up Forms B V Operating Training B V Maintenance C V A Practical Guide to Project Planning Procedures B V Effective project planning is the key to a successful and cost- effective documentation effort. More importantly, is the inte- Regulatory Applicable Codes B C Inspection Certificates C* C gration of construction with C&Q. Operating companies have Permit Documents B B different preferences: some would award construction and Validation Validation Master Plan --- V commissioning to the same construction contractor; others Validation Protocols --- V would go further and award construction and C&Q to the Validation Summary --- V same construction contractor, ensuring a successful, seam- Report less integration and quality documentation, resulting in the B: BASELINE DOCUMENT - These documents are created and retained in handover of a qualified facility rather than a merely mechani- project records with appropriate project approvals. cally completed one. (There are additional variations and C: CONTROLLED DOCUMENT - These documents are created “as built” operating company contracting preferences, which are out- retained in project files with appropriate project approvals and maintained after commissioning. (Note C* means that only some of the documents in side the scope of this article.) The construction contractor’s this category require document maintenance) role in a C&Q project can be broken down into three steps: V: VALIDATION DOCUMENT - These documents are treated as controlled documents, but with the added approvals required for validation programs. • develop and agree upon the scope of work and responsibili- Additional approvals usually are limited to Quality Assurance and operations. ties Document maintenance is a formal change control process. • agree upon a methodology and develop the project execu- Table A. Documentation requirements. tion plan and quality manual • develop a project management plan incorporating docu- neers’ drawings, the construction contractor must graphi- ment management cally delineate each system and its boundaries. This has significance for the organization of the TOP, for example, if it Each of these steps has components with a significant impact is to be organized by system; it also identifies which subcon- on documentation; therefore, the construction contractor tractor and/or vendor has responsibility for what element. should fully integrate these steps into project planning. The following is a practical guide to each step and its essential Perform Risk Analysis components. The risk analysis is an extremely important activity involv- ing the operating company and construction contractor. The Step 1: Develop and Agree Upon result will capture operating company expectations by clas- the Scope of Work and Responsibilities sifying systems into critical and/or direct impact systems and At the start of a project, it is essential for the operating non-critical and/or indirect impact systems. This is signifi- company and construction contractor to agree on the scope of cant because critical systems, such as fermentation, require work, perform a risk analysis to identify critical and non- a higher level of documentation. Thus, the risk analysis critical systems, and identify who is responsible for the culminates in establishing
Recommended publications
  • Commissioning Engineer with Experience in Regulated Industries
    Commissioning Engineer with experience in regulated industries Are you looking for a career with a sense of purpose? Our purpose is to help all our clients achieve theirs! Join a company that provides decisive and measurable solutions for complex challenges in the Life Science Industry. We can turn what can be challenging situations into actionable and realistic solutions. Among our many exciting projects, we have helped clients “Feed the World,” “Detect Cancer Early, When it Can be Cured,” “Create the First Bioengineered Human Acellular Vessel (HAV),” and “Lower the Cost of Life-Saving Pharmaceutical and Biotechnology Products to Improve the Life of All Patients”. PEG is a full-service program, project, cost, and construction management firm that delivers customized innovative solutions focused on the Life Science industry. We work on a variety of project sizes and types and our expert, in-house team provides program and project management, construction management, cost estimating and management, scheduling, and commissioning services. We are a Service-Disabled Veteran-Owned Small Business (SDVOSB), North Carolina state HubZone certified, and a State of Virginia Small, Women-owned, and Minority-owned Business (SWaM) firm that offers a host of project support services to clients nationwide. This is a full-time, permanent position in a fast-paced environment. The role could alternate between our HQ office located in the Research Triangle Park, NC, and Client's locations. Job Overview: Commissioning engineers perform commissioning testing on facilities and manufacturing equipment; author commissioning plans, risk assessments, commissioning protocol, and standard operating procedures; and, provide client support for projects either independently or as part of a larger team.
    [Show full text]
  • Orange Book Cumulative Supplement 7 July 2006
    CUMULATIVE SUPPLEMENT 07 July 2006 APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS 26th EDITION Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research Office of Generic Drugs 2006 Prepared By Office of Generic Drugs Center for Drug Evaluation and Research Food and Drug Administration APPROVED DRUG PRODUCTS with THERAPEUTIC EQUIVALENCE EVALUATIONS 26th EDITION Cumulative Supplement 07 July 2006 CONTENTS PAGE 1.0 INTRODUCTION ........................................................................................................................................ iii 1.1 How to use the Cumulative Supplement ........................................................................................... iii 1.2 Applicant Name Changes.................................................................................................................. iv 1.3 Availability of the Edition ................................................................................................................... vi 1.4 Report of Counts for the Prescription Drug Product List ................................................................... vi 1.5 Zocor (simvastatin) Patent Relisting.................................................................................................viii 1.6 Cumulative Supplement Legend ....................................................................................................... vi DRUG PRODUCT LISTS Prescription Drug Product List ......................................................................................................
    [Show full text]
  • 9894 Pharma Tech Media Planner V6 2007
    www.pharmtech.com years 1977– 2007 30ANNIVERSARY CELEBRATING 30 YEARS AS THE 2007 INDUSTRY’S MOST AUTHORITATIVE SOURCE Media Planner years 1977–2007 ANNIVERSARY years 1977–2007 ANNIVERSARY THE PHARMACEUTICAL TECHNOLOGY BRAND PUBLISHER’S STATEMENT Pharmaceutical Technology’s authoritative reputation and powerful brand recognition within the pharmaceutical/biopharmaceutical development & manufacturing marketplace will help you establish and maintain your own strong brand among pharma industry decision makers. A circulation of 38,667 BPA-qualified subscribers* and unmatched peer written and reviewed editorial make Pharmaceutical Technology an invaluable resource within top pharma companies, as well as small, specialty and biotech pharma companies spending billions each year on pharmaceutical development and manufacturing. Please celebrate with us as Pharmaceutical Technology marks its 30th Anniversary as the industry leader. —Michael Tracey, Publisher % 90 of readers rated Pharmaceutical Technology as important or very important to them as a professionalˆ EDITORIAL MISSION Pharmaceutical Technology publishes authoritative, reliable, and timely peer-reviewed research and expert analyses for scientists, engineers, technicians, and managers engaged in process development, manufacturing, formulation, analytical technology, packaging and regulatory compliance in the pharmaceutical and biotechnology industries. —Douglas McCormick, Editor in chief www.pharmtech.com *BPA June 2006 Statement ^2006 Readership Study Conducted by Advanstar Research
    [Show full text]
  • Audit Final Pn 5-28-04
    Appendix Radio Radio Callsign Service Licensee State Callsign Service Licensee State KA26590 IG MDOI INC TX KA96512 IG PM REALTY GROUP TX KA2774 PW OXFORD, VILLAGE OF MI KAA245 IG YELLOW & CITY CAB CO KS KA3917 IG SCRANTON TIMES PA KAD598 PW RED OAK VETERINARY CLINIC IA KA40009 IG GADSDEN, CITY OF AL KAE933 IG FOODSERVICE MANAGEMENT GROUPFL INC KA40058 IG HOUMANN, JIM:HOUMANN, CHETND KAG551 PW COOK, RICHARD L MO KA42246 IG HOUSTON FLEA MARKET INC TX KAH411 IG MIKE HOPKINS DIST CO INC TX KA42563 IG MUIRFIELD VILLAGE GOLF CLUBOH KAH535 PW CEDAR RAPIDS, CITY OF IA KA4305 IG CITY OF LOS ANGELES DEPARTMENTCA OF KAJ418WATER & POWERIG KOPSA, LEO E IA KA43600 IG SHAPLEY, CHARLES P MO KAM394 IG CROOKSTON IMPLEMENT CO INCMN KA48204 PW PRESQUE ISLE, COUNTY OF MI KAM826 IG AIRGAS SOUTHWEST INC TX KA52811 IG R & R INDUSTRIES INC MA KAM951 IG TERRA INTERNATIONAL INC IA KA53323 IG ELK RIDGE LOG INC WA KAM983 IG RAY KREBSBACH & SONS IA KA53447 PW PIERCE, TOWNSHIP OF OH KAN247 IG BROCE CONSTRUCTION CO INCKS KA53918 IG B M I INC MI KAN892 PW HIAWATHA, CITY OF KS KA61058 IG THISTLE, RONALD F MA KAO274 IG MALINE, THOMAS G NE KA62473 PW KENTUCKY, COMMONWEALTH OFKY DBA KYKAP406 EMERGENCY MANAGEMENTIG DYNEGY IT INC TX KA64283 IG SAINT MARY MEDICAL CENTERWA KAP554 IG AWARE OPERATING SERVICES TXINC KA64769 IG SOUTHERN WAREHOUSING & DISTRIBUTIONFL KAQ533 LTD PW CALIFORNIA, STATE OF CA KA65089 IG DUN & BRADSTREET NJ KAQ708 PW PENNSYLVANIA, COMMONWEALTHPA OF KA65696 IG PARSONS INFRASTRUCTURE &CA TECHNOLOGYKAR785 GROUP PW PIMA, COUNTY OF AZ KA66353 IG BALTIMORE MARINE
    [Show full text]
  • Oral Delivery Oct 06 18/1/07 20:19 Page 1
    Oral Delivery Oct 06 18/1/07 20:19 Page 1 ORAL DRUG DELIVERY WHEN YOU FIND THE HOLY GRAIL www.ondrugdelivery.com Oral Delivery Oct 06 18/1/07 20:19 Page 2 “Oral drug delivery: when you find the Holy Grail” CONTENTS This edition is one in a series of sponsored themed publications from ONdrugDelivery Ltd. Each issue focuses on a specific topic within the field of drug delivery, and contain up to eight articles contributed Introductory comment by leaders in that field. Guy Furness 3 Full contact information appears alongside each article. Contributing companies would be delighted to hear Growing sales and new opportunities for oral from interested readers directly. ONdrugDelivery fast dissolve would also be very pleased to pass on to authors, or Dr Ian Muir answer as appropriate, any queries you might have in relation to this publication or others in the series. Cardinal Health 4-6 During 2007 ONdrugDelivery will be covering the following topics: From oral drug delivery technology to proprietary February: Transdermal delivery product development April: Pulmonary delivery Dr Anand Baichwal, Thomas Sciascia, MD June: Prefilled syringes Penwest Pharmaceuticals 7-10 August: Oral drug delivery October: Delivering injectables December: Nanotechnology in drug delivery Combination oral products: the time is now! Fred H. Miller To start a FREE subscription (pdf or print) to INNERCAP Technologies 12-15 ONdrugDelivery’s sponsored series, please contact ONdrugDelivery directly (details below) Combining technologies without compromise: taste masking + ODT + modified release Steve Ellul Eurand 16-19 Oral drug delivery: the Holy Grail To find out more about how your company can Ms Bavani Shankar participate in 2007, please contact ONdrugDelivery Emisphere Technologies 20-21 directly (details below).
    [Show full text]
  • Federal Register/Vol. 77, No. 115/Thursday, June 14, 2012
    Federal Register / Vol. 77, No. 115 / Thursday, June 14, 2012 / Notices 35691 TABLE 1—LIST OF SAFETY AND EFFECTIVENESS SUMMARIES FOR APPROVED PMAS MADE AVAILABLE FROM JANUARY 1, 2012, THROUGH MARCH 31, 2012—Continued PMA No., Docket No. Applicant Trade name Approval date P060008.S046, FDA–2012–M–0210 ... Boston Scientific Corp ......................... TAXUS Liberte´ Paclitaxel-Eluting Cor- February 22, 2012. onary Stent System (Monorail and Over-The-Wire Delivery Systems). P030025.S086, FDA–2012–M–0209 ... Boston Scientific Corp ......................... TAXUS Express2 Paclitaxel-Eluting February 22, 2012. Coronary Stent System (Monorail and Over-The-Wire Delivery Sys- tems). P110023, FDA–2012–M–0221 ............ ev3, Inc ................................................ Everflex Self-Expanding Peripheral March 7, 2012. Stent System (Everflex). P070004, FDA–2012–M–0250............ Sientra, Inc.......................................... SIENTRA Silicone Gel Breast Im- March 9, 2012. plants. II. Electronic Access LOCATION: The meeting will be held at submissions. In the process of Persons with access to the Internet the FDA White Oak Campus, 10903 considering these changes, FDA has may obtain the documents at http:// New Hampshire Ave., Bldg. 31 previously made available for comment www.fda.gov/MedicalDevices/ Conference Center, Great Room 1503, versions of documents that support ProductsandMedicalProcedures/ Silver Spring, MD 20993. The following making regulatory submissions in DeviceApprovalsandClearances/ link contains public meeting attendee electronic format using the (eCTD) information as well as frequently asked PMAApprovals/default.htm and http:// specifications. These draft documents questions and answers regarding public www.fda.gov/MedicalDevices/ represented FDA’s major updates to meetings at White Oak: http:// ProductsandMedicalProcedures/ Module 1 of the eCTD based on www.fda.gov/AboutFDA/ DeviceApprovalsandClearances/ previous comments.
    [Show full text]
  • Memorandum JUL 1 6 201D
    Memorandum Subject Date Additional Quota Letters Received by July 15, 2010 (DFN: 630-08.2) JUL 1 6 201D To From Christine A. Sanncrud. Ph.D., Chief "Barbar• J.Illoockholdt, Chief Drug & Chemical Evaluation Section Regul• torn Section Office of Diverison Control Off cL rl Diversion Control On July 15. 2010, this section received your e-mail requesting a review of seventeen (17) quota applications from sixteen (16) registered manufacturers to determine if there arc any pending administrative/legal actions against these applicants and to advise ODE of the findings. ODOR conducted reviews (NADDIS, CSA, etc), as well as surveyed the responsible field offices for their input and recommendations. Provided below are the results and recommendations. QUOTA APPLICANTS wan NO ADVERSE OR DEROGATORY INFORMATIO N Novartis Consumer I lealth Lincoln (10345) (b)(4);(b)(7)(E) Baxter (10346) Generics Bidco li bda Vintage (10347) Noramco Delaware (10348) Pharmaceuticals International inc. (10349) Pharmedium (10351) Pharmedium (10352) Rhodes (10356) Bio-Pharm (10357) Patheon (10358) Patheon (10359) Watson (10361) B & B (10363) lospira. Inc. NC (10364) Epic Pharma (10366) Mallinckrodt I lobart (10367) Chemtos (10368) Vol. II Page 55 2 Per consultation with the field offices. DEA does not have sufficient grounds to limit, restrict. or deny quota requests from these registrants. Based on this information. ODG suggests that you proceed with the completion of the quota applications. If you have any questions pertaining to this information. please feel free to contact me (b)(6);(b)(7)( or SC C) (b)(6);(b)(7)(C) Vol. II Page 56 Memorandum Subject Date Additional Quota Letters Received as of July 19, 201() (DFN: 630-08.2) stir 2 8 2010,., To Fr ,./"./ Christine A.
    [Show full text]
  • Helen Keller Helen Keller
    HELEN KELLER Prepared for USAID BHR/PVC GRANT NO. 3077 March 23, 1995 Contact Person: Louis D. Pizzarello, MD, MPH Medical Director Helen Keller International 90 Washington St. New York, NY 10006 A world leader ill blilldlless prer.:elllioIJ alld rehabilitotioll since 1915. WORLD HEADQUARTERS 90 WASHINGTO:-: STREET. NEW YORK, NEW YORK 10006 TEL (212) 943'()890 F.-\X (212) 943-1220 @ PROJECT SEE ANNUAL REPORT PROJECT SEE (Sustainable, Efficient, Eye Care) OCTOBER 1993-SEPTEMBER 1994 TABLE OF CONTENTS Executive Summary . • . • . • • . • . • . 1 I. Headquarters. • • . 3 ll. Mexico. • . • . • . .. 5 Ill. Morocco. • . • . • . • • . 11 IV. Philippines ....•..........•.......•...•...........•.•.. 18 V. Tanzania. ....... 25 Appendix I Childhood Blindness Technical Advisory Group (CBTAG) Forms and Guidelines Appendixll Procurement and Gifts-in-Kind per country Appendix III Headquarters and Field Organizational Charts Appendix IV Primary Eye Care Training Manual Draft Outline Appendix V Summary of Eye Disease Chihuahua State, Mexico Appendix VI Morocco Surgical Outcome Details Appendix VII Philippines Residency Training Map & Curriculum Appendix VIll 'fl Budget Pipeline October 1993-September 1994 •• PROJECrSEE ANNUAL REPORT OCTOBER 1993 - SEPTEMBER 1994 Executive Summm Project SEE ~ustainab1e, Efficient, Eye Care) is a major public health and blindness prevention effort undertaken by Helen Keller International. This project builds on progress attained through previous Matching Grant programs. Over the last year, Project SEE has successfully enhanced the ability of HKI field staff and Ministries of Health to deliver eye health and blindness prevention services to the people of Mexico, Morocco, Philippines and Tanzania. With the support of USAID and Helen Keller International, hundreds of thousands of families have access to services, not previously available to them, and in many cases, this service is now closer to home.
    [Show full text]
  • Department of Vermont Health Access Over-The-Counter (OTC) Drugs
    Department of Vermont Health Access Over-the-Counter (OTC) Drugs Report Date: 2/5/2020 DRUG CATEGORY BRAND / PA GENERIC DRUG DESCRIPTION NDC GENERI PRODUCT DESCRIPTION REQUIRED LABELER NAME C ACNE PRODUCTS Adapalene Gel 0.1% GALDERMA 00299491015 B DIFFERIN GEL 0.1% GALDERMA 00299491045 B DIFFERIN GEL 0.1% GALDERMA 00299492030 B DIFFERIN GEL 0.1% GALDERMA 00299492045 B DIFFERIN GEL 0.1% Benzoyl Peroxide Cloth 6% ACELLA PHARMACEUTICALS 42192016160 G BPO CLOTHS MIS 6% Benzoyl Peroxide Gel 10% RUGBY LABORATORIES 00536105656 G ACNE MEDICAT GEL 10% PERRIGO PHARMACEUTICALS 45802030801 G BENZOYL PER GEL 10% PERRIGO PHARMACEUTICALS 45802030896 G BENZOYL PER GEL 10% Benzoyl Peroxide Gel 2.5% PERRIGO PHARMACEUTICALS 45802010196 G BENZOYL PER GEL 2.5% Benzoyl Peroxide Gel 5% RUGBY LABORATORIES 00536105556 G ACNE MEDICAT GEL 5% PERRIGO PHARMACEUTICALS 45802021601 G BENZOYL PER GEL 5% PERRIGO PHARMACEUTICALS 45802021696 G BENZOYL PER GEL 5% Benzoyl Peroxide Liq 10% PERRIGO PHARMACEUTICALS 45802031801 G BENZOYL PER LIQ 10% WASH PERRIGO PHARMACEUTICALS 45802031834 G BENZOYL PER LIQ 10% WASH HARRIS PHARMACEUTICAL 67405083005 G BENZOYL PER LIQ 10% WASH HARRIS PHARMACEUTICAL 67405083008 G BENZOYL PER LIQ 10% WASH GLAXO CONSUMER HEALTHCARE L.P. 00145098505 G PANOXYL WASH LIQ 10% CROWN LABORATORIES 00316022855 G PANOXYL WASH LIQ 10% Benzoyl Peroxide Liq 4% CROWN LABORATORIES 00316022706 G PANOXYL WASH LIQ 4% GLAXO CONSUMER HEALTHCARE L.P. 00145266005 B PANOXYL-4 LIQ CREM WSH Benzoyl Peroxide Liq 5% PERRIGO PHARMACEUTICALS 45802028001 G BENZOYL PER LIQ 5%
    [Show full text]
  • Pharmaceutical Research and Manufacturers of America – Phrma
    The Short-Term and Long-Term Competitive Impact of Authorized Generics A Report for the Federal Trade Commission October 28, 2009 TABLE OF CONTENTS INTRODUCTION ........................................................................................................................... 1 DISCUSSION .................................................................................................................................. 3 I. LONG-TERM COMPETITIVE HARM IS UNLIKELY ................................................... 3 A. Unsupported Foreclosure Claims Have Been Made For Nearly Two Decades .................................................................................................................... 4 B. Marketplace Realities Undercut The Long-Tenn Foreclosure Theory .................... 7 1. Sales and Profitability Are Growing ........................................................... 7 2. Wall Street Valuations Are Growing ........................................................ 10 II. THE FTC PRICING ANALYSIS SHOWS $880 MILLION IN CONSUMER SAVINGS .......................................................................................................................... 14 III. CONSUMER SAVINGS SHOULD BE MEASURED USING WHOLESALE DATA AND WEIGHTED AVERAGE PRICES .............................................................. 17 A. The Wholesale Data Carries Far More Weight.. .................................................... 17 B. Average Drug Prices Should Be Volume-Weighted ............................................. 19 IV.
    [Show full text]
  • Drugs Under Patent Drugs Under Patent Drugs Under Patent Drugs Under Patent Drugs Patent Drugs Under Patent Drugs Under Paten
    Drugs Under Patent Drugs Under Patent Drugs Under Patent Drugs Under Patent Drugs Patent Drugs Under Patent Drugs Under Patent Drugs Under Patent Drugs Under Patent Under Patent Drugs Under Patent Drugs Under Patent Drugs Under Patent Drugs Under P Drugs Under Patent Drugs Under Patent Drugs Under Patent Drugs Under Patent Drugs Patent Drugs Under Patent Drugs Under Patent Drugs Under Patent Drugs Under Patent Under Patent Drugs Under Patent Drugs Under Patent Drugs Under Patent Drugs Under P Drugs Under Patent Drugs Under Patent Drugs Under Patent Drugs Under Patent Drugs Patent Drugs Under Patent Drugs Under Patent Drugs Under Patent Drugs Under Patent Under Patent Drugs Under Patent Drugs Under Patent Drugs Under Patent Drugs Under Drugs Under Patent Drugs Under Patent Drugs Under Patent Drugs Under Patent Drugs Patent Drugs Under Patent Drugs Under Patent Drugs Under Patent Drugs Under Patent Under Patent Drugs Under Patent Drugs Under Patent Drugs Under Patent Drugs Under P Drugs Under Patent Drugs Under Patent Drugs Under Patent Drugs Under Patents Drugs Patent Drugs Under Patent Drugs Under Patent Drugs Under Patent Drugs Under Patent Under Patent Drugs Under Patent Drugs Under Patent Drugs Under Patent Drugs Under P Drugs Under Patent Drugs Under Patent Drugs Under Patent Drugs Under Patent Drugs Patent DrugsDrug Under Patent Drugs Under Patent Drugs Under Patent Drugs Under Patent Under Patent Drugs Under Patent Drugs Under Patent Drugs Under Patent Drugs Under P Drugs Under Patent Drugs Under Patent Drugs Under Patent Drugs Under
    [Show full text]
  • Building Commissioning Guideline
    BUILDING COMMISSIONING GUIDELINE BY APEGM PRACTICE STANDARDS COMMITTEE June, 2002 Prepared By: M. J. Frye, P. Eng. , Chair R. Dewar, P. Eng. I. D. Kelly, P. Eng. R. I. McDowall, P. Eng. D. I. Waldman, P. Eng. 1617171166 Table of Contents 1 Overview ................................................................................................. 1 1.1 Objectives of the Guideline........................................................... 1 1.2 Definition of Commissioning........................................................ 1 1.3 Benefits of a Comprehensive Commissioning Program................. 1 1.4 Scope of the Guideline.................................................................. 3 2 Fundamentals of a Comprehensive Commissioning Program ................... 5 2.1 Introduction .................................................................................. 5 2.2 Planning ...................................................................................... 5 2.3 Preparation.................................................................................... 7 2.4 Implementation............................................................................. 9 2.4.1 Facility Start-Up Activities........................................................... 9 2.4.2 Post Construction Phase ............................................................. 12 2.5 Project Evaluation....................................................................... 13 3 Organizational Considerations ..............................................................
    [Show full text]